Company Encyclopedia
View More
name
LKPC
600789.SH
Shandong Lukang Pharmaceutical Co.,Ltd. operates as a pharmaceutical company in China. The company provides analgesics and antipyretics; gastrointestinal; endocrine; cardio-cerebrovascular; anti-infective; and other human formulation products. It offers human and veterinary active pharmaceutical ingredient; veterinary formulation; bio-pesticides; and amino acid.
3.157 T
600789.SHMarket value -Rank by Market Cap -/-

Financial Score

05/12/2025 Update
C
PharmaceuticalsIndustry
Industry Ranking110/223
Industry medianC
Industry averageC
Score Analysis
Peer Comparison
  • Criteria
    Rating
  • Profit ScoreC
    • ROE4.81%C
    • Profit Margin3.05%C
    • Gross Margin23.11%D
  • Growth ScoreC
    • Revenue YoY1.79%C
    • Net Profit YoY-52.89%D
    • Total Assets YoY-3.65%D
    • Net Assets YoY1.78%C
  • Cash ScoreB
    • Cash Flow Margin3279.66%A
    • OCF YoY1.79%C
  • Operating ScoreB
    • Turnover0.69B
  • Debt ScoreC
    • Gearing Ratio53.44%C

Valuation analysis

portai
P/E
1Y
3Y
5Y
10Y
P/E
-
Industry Ranking
-/-
  • P/E
  • Price
  • High
  • Median
  • Low
P/B
1Y
3Y
5Y
10Y
P/B
-
Industry Ranking
-/-
  • P/B
  • Price
  • High
  • Median
  • Low
P/S
1Y
3Y
5Y
10Y
P/S
-
Industry Ranking
-/-
  • P/S
  • Price
  • High
  • Median
  • Low
Dividend Yield
1Y
3Y
5Y
10Y
Dividend Yield
-
Industry Ranking
-/-
  • Dividend Yield
  • Price
  • High
  • Median
  • Low

Institutional View & Shareholder

Analyst Ratings

Rating
Percentage
    • Price
      --
    • Highest
      --
    • Lowest
      --
    News
    View More

    LKPC's application for the issuance of stocks to specific objects has been approved for registration by the China Securities Regulatory Commission

    According to the Zhitong Finance APP, LKPC announced that the company recently received the "Approval on Shandong LKPC Co., Ltd. to Issue Stocks to Specific Objects" issued by the China Securities Regulatory Commission (referred to as "CSRC") (CSRC Permit [2025] No. 2158), approving the company's application for stock issuance registration to specific objects

    Zhitong·
    SH
    600789
    -0.61%
    Zhitong·
    SH
    600789
    -0.61%

    LKPC plans to acquire equity in Hecheng Company to further optimize resource allocation

    LKPC announced plans to acquire 1.9231% equity in Shandong Lukang Hecheng Pharmaceutical Co., Ltd. to optimize resource allocation and improve operational decision-making efficiency. This equity is publicly listed for transfer by the Zoucheng Economic Development Zone Management Committee at the Shandong Property Rights Exchange Center. If the transaction is successful, LKPC will directly hold 100% equity in Hecheng Company, and the scope of consolidated financial statements will remain unchanged

    Zhitong·
    SH
    600789
    -0.61%
    Zhitong·
    SH
    600789
    -0.61%

    LKPC: Net profit in the first half of 2025 decreased by 64.38% year-on-year

    LKPC announced that its operating revenue in the first half of 2025 was 3.154 billion yuan, a year-on-year decrease of 3.83%. Net profit was 107 million yuan, a year-on-year decrease of 64.38%. Basic earnings per share were 0.12 yuan/share, a year-on-year decrease of 63.64%

    Zhitong·
    SH
    600789
    -0.61%
    Zhitong·
    SH
    600789
    -0.61%

    LKPC's subsidiary has obtained the drug registration certificate for Vardenafil Hydrochloride Tablets

    LKPC's subsidiary, Saiter, recently obtained the drug registration certificate for Vardenafil Hydrochloride Tablets issued by the National Medical Products Administration. This drug is a new registration classified as Category 4 generic drug, which has passed the consistency evaluation of quality and efficacy for generic drugs, and is suitable for the treatment of male erectile dysfunction

    Zhitong·
    SH
    600789
    -0.61%
    Zhitong·
    SH
    600789
    -0.61%

    LKPC: It is expected that the net profit in the first half of 2025 will decrease by 59.34%-65.98% year-on-year

    LKPC expects its net profit in the first half of 2025 to decrease by 59.34%-65.98% year-on-year, with a projected net profit attributable to the owners of the parent company of 102 million to 122 million yuan, a decrease of 178 million to 198 million yuan. Meanwhile, the net profit after deducting non-recurring gains and losses is expected to be 94.88 million to 108 million yuan, an increase of 3.49%-17.45% year-on-year

    Zhitong·
    SH
    600789
    -0.61%
    Zhitong·
    SH
    600789
    -0.61%
    © 2025 Longbridge｜Disclaimer